Small Molecules

14 Oct 2018 U.S. FDA approves Bayer’s Xarelto® for patients with coronary or peripheral artery disease
14 Oct 2018 Positive Late-Breaking Phase II Data Evaluating Investigational Oral Therapy, Evobrutinib in RMS
11 Oct 2018 Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients
11 Oct 2018 Pharmaxis releases positive results of phase 1 clinical trial for LOXL2 inhibitor compound
11 Oct 2018 Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya® over Copaxone® in patients with relapsing remitting multiple sclerosis
10 Oct 2018 Janssen Submits European Marketing Authorisation Application for Esketamine Nasal Spray for Treatment-Resistant Depression
10 Oct 2018 Cantrixil Phase I Study Progresses To Next Stage
10 Oct 2018 Lyra Therapeutics Presents Clinical Data for LYR-210 for Treatment of Chronic Rhinosinusitis at the American Rhinologic Society Annual Meeting
10 Oct 2018 Exelixis Initiates Phase 3 Pivotal Trial (COSMIC-311) of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy
10 Oct 2018 Celgene Announces Phase 3 STYLE Study of OTEZLA® (apremilast) in Moderate to Severe Scalp Psoriasis Met Primary Endpoint
10 Oct 2018 REVOLUTION Medicines Announces First Patient Dosed with RMC-4630 in Phase 1 Clinical Study in Patients with Advanced Solid Tumors
10 Oct 2018 NeuroVive Receives KL1333 Clinical Trial Regulatory Approval
10 Oct 2018 ObsEva SA Presents Clinical Data from Phase III IMPLANT 2 Trial of Nolasiban in IVF at the American Society of Reproductive Medicine (ASRM) Annual Meeting
09 Oct 2018 Menlo Therapeutics Announces Results from a Phase 2 Clinical Trial of Serlopitant for the Treatment of Refractory Chronic Cough
08 Oct 2018 Blueprint Medicines Announces Updated Data from Phase 1 ARROW Clinical Trial Showing Broad, Durable Activity of BLU-667 in Advanced RET-Altered Medullary and Papillary Thyroid Cancers
08 Oct 2018 Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients
06 Oct 2018 Cavion Announces Promising Phase 2 Data for Essential Tremor in T-CALM Proof-of-Concept Study
06 Oct 2018 Calithera Biosciences Announces Clinical Trial Collaboration to Evaluate IBRANCE® (palbociclib) and talazoparib in Combination with CB-839
06 Oct 2018 Progenics Reports Results of Phase 2/3 Trial of PSMA PET Imaging Agent PyL for the Detection of Prostate Cancer
06 Oct 2018 Cytokinetics and Astellas Provide Updates Regarding Collaborative Skeletal Muscle Program
05 Oct 2018 Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes
04 Oct 2018 Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Treatment-Naïve Patients
04 Oct 2018 Merck’s HIV Therapy DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens
03 Oct 2018 Genentech Announces New Data for Risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress
03 Oct 2018 Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up